

Supporting Information

Exploring the Antimicrobial Potential of Isoniazid Loaded Cu-based Metal-Organic Framework as a Novel Strategy for Effective Killing of *Mycobacterium tuberculosis*

Pawan Kumar ^{§a}, Ananyaashree Behera ^{§b}, Pranav Tiwari ^a, Sibi Karthik ^c, Mainak Biswas ^b,
Avinash Sonawane ^{bc}, and Shaikh M. Mobin ^{*acde}

^a Department of Chemistry, Indian Institute of Technology, Indore, Simrol, Madhya Pradesh, India.

^b School of Biotechnology, KIIT Deemed to be University, Bhubaneswar, Odisha, India.

^c Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Simrol, Madhya Pradesh, India.

^d Center for Advance Electronic (CAE), Indian Institute of Technology, Indore, Simrol, Madhya Pradesh, India.

^e Center for Electric Vehicle and Intelligent Transport Systems, Indian Institute of Technology, Indore, Simrol, Madhya Pradesh, India.

[§] Pawan Kumar (Design and synthesis of Cu-MOF, characterization and drug delivery) and Ananyaashree Behera (Involved in Biological studies) contributed equally to this work

* Corresponding author; Email: xray@iiti.ac.in

Telephone: +91-731-2438752

Contents

1. Characterization

2. Synthesis of **H₄L**

2.1. Synthesis of tetraethyl 5,5'-((pyridine-2,6-diylbis (methylene)) bis(oxy))diisophthalate

2.2. Synthesis of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalic acid (**H₄L**)

Schemes and Figures

Scheme 1: The systematic synthesis procedure of **H₄L**

Figure S1: HRMS Spectrum of tetraethyl 5,5'-((pyridine-2,6-diylbis(methylene)) bis(oxy))diis ophthalate

Figure S2: ¹H NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalate

Figure S3: ¹³C NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalate

Figure S4: 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalic acid (**H₄L**)

Figure S5: ¹H NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisop hthalic acid (**H₄L**)

Figure S6: : ¹³C NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisop hthalic acid (**H₄L**)

Figure S7: Activation of **IITI-3**

Figure S8: PXRD of As synthesized and Activated **IITI-3** respectively

Figure S9: Relation between **INH** and absorbance

Figure S10: DLS: Average particle sized of **IITI-3** and **INH@IITI-3**.

Figure S11: Drug release profile from **INH@IITI-3** at 5.8 and 7.2 pH with Higuchi and Zero Order Kinetics respectively

Figure S12: zeta potential of **INH@IITI-3** at pH 5.8 and 7.4 repectively

1. Characterization:


ESI-TOF-MS was used to perform high-resolution mass spectral studies (HRMS). On 500 MHz spectrometers, the ^1H and ^{13}C NMR spectra were captured. For ^1H NMR, data are presented as a chemical shift (ppm), multiplicity (singlet, doublet, triplet, quartet, multiplet), coupling constant J (Hz), integration, and assignment; for ^{13}C , data are presented as a chemical shift. NMR apparatus using Me_4Si as the internal standard in DMSO-d_6 and CDCl_3 . Monochromatic $\text{Cu-K}\alpha$ radiation (1.54 Å) was used to record the powder X-ray diffraction (PXRD) data on a Rigaku Smart-Lab X-ray diffractometer, and the tube voltage and current were 40 kV and 40 mA, respectively. FE-SEM images were recorded by JOEL-7610 F plus. The Perkin Elmer-Spectrum Two in ATR mode was used to conduct the FT-IR (Fourier Transform Infrared Spectroscopy) experiment. Thermogravimetric analysis (TGA) was performed using a Mettler Toledo (TGA/DSC 1) analyzer with STARe software and heated to 800 °C at a rate of 10 °C/min while being supplied with a continuous flow of liquid nitrogen. On an Autosorb iQ, Brunauer-Emmett-Teller (BET) surface area and Barrett-Joyner-Halenda (BJH) distribution calculations were made (Quanta chrome Instruments, version 1.11). UV-VIS data was recorded by Shimadzu's UV-1900 UV-VIS Spectrophotometer. DLS-Zeta have been recorded by The Malvern Zetasizer Nano ZSP (ZEN 5600).

2. Synthesis of H_4L :

2.1 Synthesis of tetraethyl 5,5'-((pyridine-2,6-diylbis (methylene)) bis(oxy))diisophthalate:

5-hydroxyisophthalic acid diethyl ester (10.4 mmol, 2.478 g) was placed in a round-bottom flask (RB) and agitated at 80 °C for 30 minutes while under an N_2 atmosphere. Dry acetonitrile (200 mL) and dry K_2CO_3 (26.4 mmol, 3.6 g) were added. 2,6-

Scheme 1: The systematic synthesis procedure of **H₄L**.



bis(bromomethyl)pyridine (4.528 mmol, 1.2 g) was then added to the mixture, and the resultant solution was refluxed for 24 hours. The entire combination was then allowed to cool to ambient temperature, solvent was evaporated by rotavapour and work-up three times with EtOAc:water, before passing through the anhydrous Na_2SO_4 . In the final step, EtOAc was evaporated, a white solid was obtained. A 2.492 g product yield was obtained (4.302 mmol, 95%) (Scheme 1). HRMS (ESI-TOF) m/z $[M + Na]^+$ calculated for $C_{31}H_{33}NO_{10}Na^+$ 602.1997 and found to be 602.1990 (**Figure S1**). 1H NMR (500 MHz, $CDCl_3$) δ 8.32 (s, 2H), 7.88 (d, $J = 1.2$ Hz, 4H), 7.80 (t, $J = 7.8$ Hz, 1H), 7.51 (d, $J = 7.8$ Hz, 2H), 5.29 (s, 4H), 4.40 (q, $J = 7.1$ Hz, 8H), 1.41 (t, $J = 7.1$ Hz, 12H) (**Figure S2**). ^{13}C NMR (126 MHz, $CDCl_3$) δ 165.1, 157.9, 155.5, 137.4, 131.8, 123, 120, 119.5, 70.4, 61, 13.8. (**Figure S3**)

2.2 Synthesis of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalic acid (**H₄L**):

Using 20 mL of 6(N) KOH solution, the chemical produced as above (4.302 mmol, 2.492 g) was refluxed in MeOH for 24 hours. The resultant solution was acidified with 6(N) HCl solution after cooling to 5 °C to produce a white precipitate. Then the white precipitate was filtered out and carefully cleaned before being dried in the air. A yield of 1.6 g of product was

discovered (3.424 mmol, 79 %). HRMS (ESI-TOF) m/z $[M - H]^-$ calculated for $C_{23}H_{16}NO_{10}^-$ 466.0769 and found to be 466.0768 (**Figure S4**). 1H NMR (500 MHz, DMSO) δ 8.11 (s, 2H), 7.89 (t, $J = 7.8$ Hz, 1H), 7.72 (s, 4H), 7.50 (d, $J = 7.7$ Hz, 2H), 5.29 (s, 5H) (**Figure S5**). ^{13}C NMR (126 MHz, DMSO) δ 167.4, 158.2, 156.2, 138.4, 134.6, 123.1, 121.1, 119, 70.6 (**Figure S6**).

Display Report

Analysis Info

Analysis Name D:\soniazid Drug delivery papers\Data\Mass data\h chem smm-pp-e3_RA2_01_23703.d
Method 8. LCMS tune wide MeOH.m
Sample Name h chem smm-pp-e3
Comment

Acquisition Date 03-Mar-23 4:34:04 PM

Operator IIT Indore

Instrument micrOTOF-Q 228888.10348

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	2.0 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	250 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	650.0 Vpp	Set Divert Valve	Waste






Figure S1: HRMS Spectrum of tetraethyl 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalate.




Figure S2: ¹H NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalate.




Figure S3: ¹³C NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalate.

Display Report

Analysis Info
Analysis Name D:\Isoniazid Drug delivery papers\Data\Mass data\H chem smm-pp-p1- RA1_01_19331.d
Method 4. LCMS tune low ACN - m
Sample Name H chem smm-pp-p1-
Comment
Acquisition Date 08-Jul-22 4:56:13 PM
Operator IIT Indore
Instrument micrOTOF-Q 228888.10348

Acquisition Parameter

Source Type	ESI	Ion Polarity	Negative	Set Nebulizer	2.0 Bar
Focus	Not active	Set Capillary	3500 V	Set Dry Heater	250 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	150.0 Vpp	Set Divert Valve	Waste






Figure S4: 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalic acid (**H₄L**).




Figure S5: ^1H NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalic acid.




Figure S6: ^{13}C NMR of 5,5'-((pyridine-2,6-diylbis(methylene))bis(oxy))diisophthalic acid.




Figure S7: Activation of IITI-3.




Figure S8: PXRD of As synthesized and Activated IITI-3 respectively.




Figure S9: Relation between INH and absorbance.



Figure S10: DLS: Average particle sized of IITI-3 and INH@IITI-3.




Figure S11: Cumulative drug release from INH@IITI-3 at pH 5.8 and 7.4 with Higuchi and zero order kinetics respectively.




Figure S12: zeta position of INH@IITI-3 at pH 5.8 and 7.4 respectively.